The PI3K/AKT pathway promotes gefitinib resistance in mutant <i>KRAS</i> lung adenocarcinoma by a deacetylase‐dependent mechanism

Victor Jeannot(Bracco (Switzerland)), Amandine Hurbin(Agir Pour les Maladies Chroniques)

International Journal of Cancer

November 8, 2013

10.1002/ijc.28594

Cited by 57

Related Papers

Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer

|Journal of Controlled Release|2018|88

Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma

|OncoTargets and Therapy|2016|36

The pyrrolopyrimidine colchicine-binding site agent PP-13 reduces the metastatic dissemination of invasive cancer cells in vitro and in vivo

|Biochemical Pharmacology|2018|17